Back to News
Market Impact: 0.2
Fusion's H1 Revenue Drop In FY27 Addressed At Annual General Meeting; Shares Plunge By Over 35%
Source: Nasdaq
Corporate EarningsCompany Fundamentals
Fusion Antibodies plc discussed its results for the first half of fiscal 2027, ending September 30, 2026, at its Annual General Meeting. The company noted lower-than-expected revenues; the available article excerpt ends before providing figures or further context.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
FAB-0.45
More News
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'
- Wall Street's fear gauge is ripping. Traders see it going even higher
- All the news about the iPhone Duo
- The Tesla Roadster should go into production in 2028, but don't get your hopes up
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test